Description:
Researchers are evaluating Tumor-agnostic biomarkers to guide therapies across tumor types, using shared molecular signals rather than tissue origin.
This approach aims to match patients to effective drugs faster, with fewer side effects and broader eligibility, potentially helping more people.
How to create new field